Baird raised the firm’s price target on Boston Scientific (BSX) to $128 from $123 and keeps an Outperform rating on the shares. The firm said they remain buyers of the shares following its investor day which increased conviction in its premium growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $132 from $131 at Canaccord
- Boston Scientific’s Strong Growth Potential and Strategic Positioning Justify Buy Rating
- Boston Scientific’s Promising Growth Trajectory: A Buy Rating Backed by Strong Financial Targets and Key Franchises
- Boston Scientific’s Promising Growth Trajectory: Buy Rating Supported by Innovative Products and Strategic Expansion
- Strong Buy Rating for Boston Scientific: Promising Growth and Profitability Outlook